GNTA Stock Skyrockets 300% Pre-Market Toward Record Highs: What’s Driving The Super Rally?

• Genenta Science shares surged 300% in premarket trading on Friday after announcing an expanded collaboration with ANEMOCYTE.
• The partnership aims to advance an off-the-shelf LVV Plasmid DNA platform to improve gene therapy production.
• Genenta Science is a clinical-stage biotech company focused on developing immuno-oncology therapies.

Genenta Science (GNTA) stock is set to hit an all-time high on Friday after the company announced that it has joined forces with biotech manufacturing organization ANEMOCYTE to develop tools for gene and cell therapy. 

At the time of writing Genenta Science stock traded over 300% higher in Friday’s premarket. On Stocktwits, retail sentiment around the stock jumped to ‘extremely bullish’ from ‘bearish’ territory the previous day. Message volume improved to ‘extremely high’ from ‘low’ levels in 24 hours. 

The collaboration centers on developing an off-the-shelf lentiviral vector (LVV) Plasmid DNA technology platform to boost the production of high-quality genetic materials used in advanced therapies.

Expanded Partnership

The new strategic agreement strengthens an already productive relationship between the two firms, previously focused on Plasmid DNA manufacturing. 

The companies intend to combine Genenta’s experience with LVV Plasmid DNA technology, originally derived from the research of co-founder Professor Luigi Naldini, with ANEMOCYTE’s production capabilities to deliver dependable materials for research and clinical applications.

What Is Genenta Science Known For? 

Genenta Science is a clinical-stage biotech company focused on developing immuno-oncology therapies that harness hematopoietic stem cells to fight tumor cancers. Its lead candidate, Temferon, is engineered to deliver immune-activating payloads directly within the tumor microenvironment through modified bone marrow-derived cells, aiming for a precise and lasting anti-cancer effect.

“By making our clinically validated LVV Plasmid DNA technology platform available to ANEMOCYTE and its clients, we are contributing to the reliable and scalable development of advanced therapy programs across the industry.”

-Pierluigi Paracchi, CEO, Genenta Science.

Genenta Science's stock has lost over 25% in 2025 and over 39% in the last 12 months. 

Also See: Alphabet, Apple, Meta Lead Private Funding For Trump’s ‘Big, Beautiful’ $250M White House Ballroom Project, Donor List Reveals

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Share

·

Add us on